Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN) is set to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Organon & Co. to post earnings of $1.05 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Up 1.0 %

OGN opened at $18.71 on Thursday. Organon & Co. has a 12 month low of $10.84 and a 12 month high of $24.79. The stock has a 50-day moving average of $18.14 and a 200 day moving average of $15.67. The firm has a market cap of $4.78 billion, a P/E ratio of 4.68, a P/E/G ratio of 0.85 and a beta of 0.83.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 5.99%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.’s dividend payout ratio is currently 28.00%.

Insider Buying and Selling

In related news, insider Kirke Weaver acquired 2,720 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the acquisition, the insider now directly owns 15,181 shares in the company, valued at approximately $278,723.16. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.17% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upped their target price on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.